METHOD FOR SURGICAL MANAGEMENT OF THROUGH MACULAR RUPTURES USING AUTOLOGOUS PLATELET-RICH PLASMA Russian patent published in 2024 - IPC A61F9/07 A61K35/19 A61P27/02 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to ophthalmosurgery, and can be used in surgical treatment of through macular retinal ruptures by blocking rupture with autologous platelet-rich plasma (PRP). That is ensured by sampling 10 ml of patient’s venous blood immediately before the operation. Transconjunctival sutureless three-port vitrectomy 25 G is performed. A posterior hyaloid membrane and an internal boundary membrane are removed. One drop of the PRP fraction, which is the richest in thrombocytes, is applied on the macular area at the rupture without trying to get into the hole itself. Formed pulp-like PRP is moved directly into the rupture with forceps or shifted by the tip of the vitreous tube, completely filling its cavity. Excess PRP is removed from the macular region with the help of a vitreotome, and the intervention is completed by air tamponade.

EFFECT: invention provides higher efficiency of surgical intervention due to achievement of complete closure of rupture and improvement of visual functions, reduction of traumatism of operation due to provision of complete blocking of rupture by plasma without trauma of retinal area and choroid with cannulas, reducing the risk of postoperative complications by removing excess PRP from the macular surface, which eliminates the risk of part of the PRP coming out into the anterior chamber with formation of fibrin films.

1 cl, 1 ex